Details of the Drug

General Information of Drug (ID: DMM5JAN)

Drug Name

LY2495655

Indication

Disease Entry	ICD 11	Status	REF
Disuse muscle atrophy	8B61	Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 8 (GDF-8)	TTSWPH8	GDF8_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Disuse muscle atrophy

ICD Disease Classification

8B61

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Growth/differentiation factor 8 (GDF-8)	DTT	MSTN	1.64E-01	-0.06	-0.06

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01505530) A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer. U.S. National Institutes of Health.
2	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.